Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ACHE | P22303 | 1/20 | 0.32 |
| ▸ | GAA | P10253 | 1/20 | 0.31 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL32662523 | 0.76 | ACHE (0.33) | ACHE | |
| SCHEMBL21754365 | 0.69 | PKN2 (0.35) | GAAL3MBTL1 | |
| SCHEMBL31684552 | 0.69 | AKT1 (0.36) | ACHE | |
| SCHEMBL5901532 | 0.68 | CA12 (0.31) | — | |
| SCHEMBL24796839 | 0.68 | KDM4E (0.33) | ACHE | |
| SCHEMBL15987297 | 0.68 | DAPK3 (0.33) | — | |
| SCHEMBL6687949 | 0.67 | SIGMAR1 (0.40) | — | |
| SCHEMBL31684557 | 0.67 | OPRL1 (0.47) | — | |
| SCHEMBL20836293 | 0.67 | PTPN1 (0.31) | — | |
| SCHEMBL4187867 | 0.66 | HCAR1 (0.41) | L3MBTL1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-115232138-B | Huperzine A intermediate and nontoxic synthesis process of raw materials thereof | 杭州师范大学 | 2024-01-30 | — | — | CN | claimed |
| CN-115232138-A | Huperzine A intermediate and nontoxic synthesis process of raw materials thereof | 杭州师范大学 | 2022-10-25 | — | — | CN | claimed |
| CN-115232138-B | Huperzine A intermediate and nontoxic synthesis process of raw materials thereof | 杭州师范大学 | 2024-01-30 | — | — | CN | disclosed |
| CN-115232138-A | Huperzine A intermediate and nontoxic synthesis process of raw materials thereof | 杭州师范大学 | 2022-10-25 | — | — | CN | disclosed |
| US-20100197679-A1 | COMPOUNDS | GLAXO GROUP LIMITED | 2010-08-05 | — | — | US | disclosed |
| US-20100197679-A1 | COMPOUNDS | GLAXO GROUP LIMITED | 2010-08-05 | — | — | US | disclosed |
| US-7605265-B2 | Heterodimers and methods of using them | Biotechnology Research Corporation Ltd. (CN) | 2009-10-20 | — | — | US | disclosed |
| US-7605265-B2 | Heterodimers and methods of using them | Biotechnology Research Corporation Ltd. (CN) | 2009-10-20 | — | — | US | disclosed |
| WO-2009120774-A2 | METHOD OF PREPARING HUPERZINE A AND DERIVATIVES THEREOF | DEBIOPHARM S.A. (CH) | 2009-10-01 | — | — | WO | disclosed |
| US-20090247754-A1 | METHOD OF PREPARING HUPERZINE A AND DERIVATIVES THEREOF | DEBIOPHARM S.A. | 2009-10-01 | — | — | US | disclosed |
| US-20090247754-A1 | METHOD OF PREPARING HUPERZINE A AND DERIVATIVES THEREOF | DEBIOPHARM S.A. | 2009-10-01 | — | — | US | disclosed |
| US-20090247754-A1 | METHOD OF PREPARING HUPERZINE A AND DERIVATIVES THEREOF | DEBIOPHARM S.A. | 2009-10-01 | — | — | US | disclosed |
| WO-2008128961-A1 | COMPOUNDS | GLAXO GROUP LIMITED (GB) | 2008-10-30 | — | — | WO | disclosed |
| WO-2008091901-A1 | HETERODIMERS AND METHODS OF USING THEM | BIOTECHNOLOGY RESEARCH CORPORATION LIMITED (CN) | 2008-07-31 | — | — | WO | disclosed |
| US-20080176308-A1 | Heterodimers and Methods of Using Them | BIOTECHNOLOGY RESEARCH CORPORATION LIMITED (CN) | 2008-07-24 | — | — | US | disclosed |
| US-20080176308-A1 | Heterodimers and Methods of Using Them | BIOTECHNOLOGY RESEARCH CORPORATION LIMITED (CN) | 2008-07-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100197679-A1 | COMPOUNDS | NRDC, MRPL21, NISCH | ACHE 886/4885GAA 1601/4885L3MBTL1 1818/4885 |
| US-20090247754-A1 | METHOD OF PREPARING HUPERZINE A AND DERIVATIVES THEREOF | DHPS, CYP4Z1, CYP3A5 | ACHE 229/4885GAA 568/4885L3MBTL1 4536/4885 |
| US-20080176308-A1 | Heterodimers and Methods of Using Them | GRIN2A, GRIN3A, GRIN1 | ACHE 93/4885GAA 2958/4885L3MBTL1 1301/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.